{"name":"ARCAGY/ GINECO GROUP","slug":"arcagy-gineco-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-03-30","label":"vargatef Phase 3 readout (Systemic Sclerosis, Interstitial Lung Disease)","drug":"vargatef","drugSlug":"vargatef","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Chemotherapy - Bevacizumab","genericName":"Chemotherapy - Bevacizumab","slug":"chemotherapy-bevacizumab","indication":"Colorectal cancer","status":"phase_2"},{"name":"Paraplatin","genericName":"Paraplatin","slug":"paraplatin","indication":"Breast cancer","status":"phase_3"},{"name":"atezolizumab + avastin + platinum-based chemotherapy","genericName":"atezolizumab + avastin + platinum-based chemotherapy","slug":"atezolizumab-avastin-platinum-based-chemotherapy","indication":"Advanced or metastatic non-small cell lung cancer (NSCLC)","status":"phase_3"},{"name":"placebo + avastin + platinum-based chemotherapy","genericName":"placebo + avastin + platinum-based chemotherapy","slug":"placebo-avastin-platinum-based-chemotherapy","indication":"Ovarian cancer (likely, given ARCAGY/GINECO GROUP focus on gynecologic malignancies)","status":"phase_3"},{"name":"vargatef","genericName":"vargatef","slug":"vargatef","indication":"Idiopathic pulmonary fibrosis","status":"discontinued"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"carboplatin and liposomal doxorubicin","genericName":"carboplatin and liposomal doxorubicin","slug":"carboplatin-and-liposomal-doxorubicin","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Chemotherapy - Bevacizumab","genericName":"Chemotherapy - Bevacizumab","slug":"chemotherapy-bevacizumab","phase":"phase_2","mechanism":"Inhibits vascular endothelial growth factor A (VEGF-A)","indications":["Colorectal cancer","Breast cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"Paraplatin","genericName":"Paraplatin","slug":"paraplatin","phase":"phase_3","mechanism":"Small molecule","indications":["Breast cancer","Malignant tumor of ovary"],"catalyst":""},{"name":"atezolizumab + avastin + platinum-based chemotherapy","genericName":"atezolizumab + avastin + platinum-based chemotherapy","slug":"atezolizumab-avastin-platinum-based-chemotherapy","phase":"phase_3","mechanism":"This combination uses an immune checkpoint inhibitor to block PD-L1, an anti-angiogenic monoclonal antibody to inhibit VEGF-mediated tumor blood vessel formation, and platinum-based chemotherapy to directly damage tumor DNA.","indications":["Advanced or metastatic non-small cell lung cancer (NSCLC)","Ovarian cancer (platinum-sensitive recurrent or advanced)"],"catalyst":""},{"name":"carboplatin and liposomal doxorubicin","genericName":"carboplatin and liposomal doxorubicin","slug":"carboplatin-and-liposomal-doxorubicin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"placebo + avastin + platinum-based chemotherapy","genericName":"placebo + avastin + platinum-based chemotherapy","slug":"placebo-avastin-platinum-based-chemotherapy","phase":"phase_3","mechanism":"This combination uses platinum-based chemotherapy to damage cancer cell DNA while bevacizumab (Avastin) blocks tumor blood vessel formation, with placebo as a control arm.","indications":["Ovarian cancer (likely, given ARCAGY/GINECO GROUP focus on gynecologic malignancies)"],"catalyst":""},{"name":"vargatef","genericName":"vargatef","slug":"vargatef","phase":"discontinued","mechanism":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","indications":["Idiopathic pulmonary fibrosis","Interstitial fibrosis","Non-small cell lung cancer","Systemic sclerosis associated interstitial lung disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5sNlFqQ1FwMlJBOF9sWFNkTWp3bk1EY0w2M054alJuVWpOWE1SWjg3Y3Bjckw2dFJrZkFFYm5idHJJckNNeFhDcUJzTzBBZ2J4RDFuRkxRYTYxbkJoMWxB?oc=5","date":"2025-08-26","type":"trial","source":"Nature","summary":"Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature","headline":"Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized pha","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5DRzhuc2QzR09OLXhnR1dQYUItTExCU2dUY3VCdE9YXy1EMURjTFFTTVRYWFNqLWo0RTVNV2pBSkF3MzdrODlUaFB6cU9DTmNINjlsdE9xNzljcWlURE53?oc=5","date":"2024-07-16","type":"trial","source":"Nature","summary":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial - Nature","headline":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clini","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":1,"phase_3":3,"phase_1":1,"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}